Select one of the following discussion prompts to address:
Consider the following scenario: Your patient has suffered from schizophrenia for two decades and has received classic dopaminergic treatments since the onset of illness. The latest research supporting use of the glutamatergic model has not been tried on your patient, and there is an opportunity for your patient to enter clinical trials utilizing glutamate-based treatments. Your patient suffers significant executive function impairment and memory impairment. Do you recommend participation in the clinical trial? Why or why not?
Discuss the pathophysiology of cerebrovascular accidents (CVAs)—thrombotic, embolic, hemorrhagic, and lacunar—their incidence and prevalence, clinical manifestations, evaluation, and treatment.
Discuss the characteristics of common headaches—migraine, cluster, and tension—and describe their evaluation and treatment options. What prevention strategies would you advise?
Use at least one scholarly source other than your textbook to connect your response to national guidelines and evidence-based research in support of your ideas.
Book:
Pathophysiology: The Biologic Basis for Disease in Adults and Children
Author: Kathryn L. McCance and Sue E. Huether
Publisher: Elsevier
Edition: 7th (2014)
Availability: Available in your Vital Source Bookshelf
Publication Manual of the American Psychological Association
Author: American Psychological Association
Publisher: American Psychological Association
Edition: 7th
Availability: Available in your VitalSource Bookshelf (from previous terms)